

1 **Effectiveness of Ferritin-guided Donation Intervals in Blood Donors: Results of the Stepped-wedge**

2 **Cluster Randomized FIND'EM Trial**

3 Amber Meulenbeld^{1,2}, a.meulenbeld@sanquin.nl

4 Steven Ramondt^{1,3}, s.ramondt@vu.nl

5 Maike G. Sweegers¹, m.sweegers@nki.nl

6 Franke A. Quee^{1,2}, f.quee@sanquin.nl

7 Femmeke J. Prinsze¹, f.prinsze@sanquin.nl

8 Emiel O. Hoogendijk^{4,5}, e.hoogendijk@amsterdamumc.nl

9 Dorine W. Swinkels^{6,7}, dorine.swinkels@radboudumc.nl

10 Katja van den Hurk^{1,2}, k.vandenhurk@sanquin.nl

11 1. Donor Studies, Donor Medicine Research, Sanquin Research, Amsterdam, the Netherlands;

12 2. Department of Public and Occupational Health, Amsterdam Public Health research institute,
13 Amsterdam UMC, Amsterdam, the Netherlands;

14 3. Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, the
15 Netherlands;

16 4. Department of Epidemiology and Data Science, Amsterdam Public Health research institute,
17 Amsterdam UMC, Amsterdam, the Netherlands;

18 5. Department of General Practice, Amsterdam Public Health research institute, Amsterdam
19 UMC – Location VU University medical center, Amsterdam, the Netherlands;

20 6. Department of Laboratory Medicine, Radboud University Nijmegen, Nijmegen, Gelderland,
21 The Netherlands;

22 7. Center for Iron Disorders Sanquin, Sanquin Blood Supply Foundation, Amsterdam, Noord-
23 Holland, The Netherlands.

24

25 **Running head:** FIND'EM: A stepped-wedge trial of ferritin monitoring in blood donors

26 **Words** (max. 3000): 2,997

27

28 **Corresponding author**

29 Amber Meulenbeld

30 Sanquin Research

31 Plesmanlaan 125

32 PO box 9137

33 1006 AC Amsterdam, the Netherlands

34 E-mail: a.meulenbeld@sanquin.nl

35 **Key Points**

36 **Question**

37 Are ferritin-guided donation intervals effective in diminishing iron deficiency and low hemoglobin in
38 whole blood donors?

39

40 **Findings**

41 In this stepped-wedge cluster randomized trial with 412,888 donors and 1,643,700 donations,
42 ferritin-guided donation intervals were associated with a significant improvement in hemoglobin and
43 ferritin levels and decreased donor return rates. Data did not suggest improved self-reported health
44 outcomes.

45

46 **Meaning**

47 Ferritin-guided donation intervals, in addition to hemoglobin monitoring, as part of the donor iron
48 management strategy of blood establishments effectively reduce the prevalence of iron deficiency
49 and anemia in whole blood donors, but additional efforts to retain donors are required.

50 **Abstract**

51 **Importance** Blood donors are at increased risk for iron deficiency. Current hemoglobin (Hb)
52 monitoring policies are inadequate and iron management strategies are warranted.

53 **Objective** To determine the effects of ferritin-guided donation intervals for whole blood donors on
54 Hb and ferritin levels, Hb deferral, iron deficiency (ferritin < 15 ng/mL) prevalence, donor return, iron
55 deficiency-related symptoms, and the blood supply.

56 **Design, setting and participants** Between November 2017 and November 2019 a ferritin-guided
57 donation interval policy was implemented and evaluated through a stepped-wedge cluster-
58 randomized controlled trial in all blood collection centers in the Netherlands. During the study
59 period, 412,888 donors visited the blood bank.

60 **Interventions** Ferritin was measured in new donors and at every 5th whole blood donation.
61 Subsequent donation intervals were extended to six months if ferritin is $15 \leq 30$ ng/mL and to twelve
62 months if ferritin is <15 ng/mL.

63 **Main outcomes and Measures** Primary outcomes are ferritin and Hb levels, iron deficiency, Hb
64 deferral, and donor return. Secondary outcomes are self-reported iron deficiency-related symptoms.
65 Yearly donor and donation statistics were used to assess the impact on the blood supply.

66 **Results** We measured 36,099 donors, median age 43 years and 52% female, making 37,621
67 donations during the study period. Ferritin-guided donation intervals were associated with increased
68 log-transformed ferritin levels at all time points in the trial, up to 0.24 log₁₀ ng/mL as compared to
69 baseline (95% CI 0.22 – 0.27, p <0.001). Hb increased as well, up to 0.37 g/dL (95% CI 0.31 – 0.43, p
70 <0.001). Decreased odds of 85% (95% CI OR 0.10 – 0.21, p <0.001) for iron deficiency and 77% (95%
71 CI OR 0.11 – 0.41, p <0.001) for Hb deferral were reported compared to baseline. Odds of donor
72 return decreased over the course of the trial, with as much as 40% (95% CI OR 0.51 – 0.67, p <0.001).
73 We found no evidence for improved self-reported iron deficiency-related symptoms after
74 implementation of the new policy. More invitations had to be sent to donors to obtain one donation
75 and the average donation frequency per year decreased.

76 **Conclusion and Relevance** Ferritin-guided donation intervals were significantly associated with
77 increasing overall Hb and ferritin levels, thereby decreasing the prevalence of iron deficiency and Hb
78 deferrals in whole blood donors. Ferritin-guided donation intervals seem beneficial for Hb levels and
79 iron maintenance, but additional efforts are required to retain donors and to remedy self-reported
80 iron deficiency-related symptoms.

81 **Trial Registration** This trial has been registered in the Dutch trial registry (NTR6738) on September
82 29th, 2017 (<https://trialsearch.who.int/Trial2.aspx?TrialID=NTR6738>).

83

84 Key words: blood donation, donation interval, donor health, stepped-wedge cluster randomized trial,
85 ferritin

86 **Introduction**

87 Annually, more than 100 million whole blood donations are made worldwide to provide life-saving
88 treatment for patients requiring transfusion.¹ Whole blood donors that donate repeatedly are at risk
89 of developing iron deficiency and subsequent anemia.² Male donors lose approximately 8% of their
90 total iron stores with each whole blood donation, whereas menstruating women lose on average
91 81% of their total iron stores.³⁻⁵ Iron stores can be monitored through measuring ferritin. Iron
92 deficiency, ferritin levels <15 ng/ml, presents in approximately 15.0% of female and 9.4% of male
93 Dutch repeat donors.⁶

94

95 There is no consensus on iron management strategies for donor health, but key approaches include
96 extended donation intervals and iron supplementation.⁷⁻⁹ Concerns about negative perceptions, side
97 effects, and low compliance may favor extended donation intervals.^{9,10} In previous studies, extended
98 donation intervals were associated with lower risk of Hb deferrals.^{11,12} The INTERVAL trial showed
99 that longer donation intervals led to significantly higher Hb and ferritin levels.¹² Most blood
100 establishments monitor Hb to protect donor health, prevent anemia and ensure sufficient Hb content
101 in the product, deferring blood donors with Hb levels below 13.5 g/dL (males) or 12.5 g/dL
102 (females).^{7-9,13-15} However, iron deficiency can present without anemia, especially in repeat donors.
103 As Hb levels do not reflect iron stores, the current standard is insufficient to maintain proper iron
104 reserves. The World Health Organization (WHO) advises additional monitoring of ferritin to detect
105 iron deficiency and monitor donor health.¹⁶

106

107 In 2017, Sanquin Blood Bank in The Netherlands implemented a nationwide policy for iron
108 monitoring of whole blood donors. In addition to the Hb measurement at the pre-donation
109 screening, ferritin is measured at the first visit of new donors and after every fifth whole blood
110 donation of repeat donors. If ferritin is between 15 and 30 or below 15 ng/mL, the subsequent
111 donation interval is extended to six or twelve months, respectively. A stepped-wedge approach was

112 used to evaluate the effects of this ferritin-guided donation interval policy for whole blood donors on
113 (1) Hb and ferritin levels, (2) iron deficiency, (3) Hb deferral, (4) donor return rates, (5) self-reported
114 iron deficiency-related symptoms, and (6) the blood supply.

115

116 **Methods**

117 *Design*

118 Ferritin measurement IN Donors—Effectiveness of iron Monitoring (FIND’EM) is a stepped-wedge
119 cluster randomized trial, described in detail by Sweegers et al.¹⁷ We conducted cross-sectional ferritin
120 measurements before, during, and after implementing a new policy for all donors visiting a blood
121 collection center during pre-selected weeks. We measured ferritin in stored plasma samples from
122 donors who consented to use their leftover donations for medical research. Additionally, optional
123 questionnaires were offered to donors. The trial was powered on 4ng/mL change in the ferritin level
124 outcome over six months, assuming a SD of 54 ng/mL, ICC of 0.10 and 150 visits per donation
125 center.¹⁷ The policy and implementation strategy was approved by Sanquin’s Medical and Ethical
126 Advisory Board. The trial was approved by Sanquin’s Board of Directors.

127

128 *Randomization*

129 The 138 fixed and mobile blood collection centers in the Netherlands are divided over 29 staffing
130 clusters that we randomly assigned to four randomization groups. The stepped-wedge design
131 involved random and sequential rollout of ferritin-guided donation intervals in all 29 clusters by
132 randomization group from November 2017 to November 2019. The allocation was not concealed and
133 the planned timing of the rollout was revealed before the study. Donors were notified of the new
134 policy through letters upon implementation at their regular donation center.

135

136 *Procedures*

137 As part of routine procedures, donors undergo a health screening to assess their eligibility to donate
138 by measuring Hb levels and blood pressure and assessing recent travel, sexual and medical history
139 prior to every donation. In the Netherlands, donors also make a pre-donation screening visit prior to
140 their first donation. In accordance with European legislation, Hb cut-offs for donor eligibility are
141 >13.5 g/dL for males and >12.5 g/dL for females.¹⁸ Donors with low Hb (capillary measurement prior
142 to donation with HemoCue 201, Angelholm, Sweden) are deferred for 3 months. If eligible, males can
143 donate every 56 days up to five times a year, females every 122 days up to three times a year,
144 independent of menopausal status.

145

146 The intervention entails extended donation intervals based on ferritin measurements. The cut-offs
147 for extended intervals were based on definitions for iron deficiency (<15 ng/mL, 12 months deferral)
148 and reduced iron levels (\leq 30 ng/mL, 6 months deferral) by Alvarez-Ossorio et al.⁹ The six month
149 interval is based on the results from Schotten et al., suggesting intervals of at least 180 days are
150 required to fully replete iron stores after donation.⁸ A twelve month interval is indicated for iron
151 deficient donors to replete to higher levels than pre-donation. In whole blood donors, ferritin is
152 measured at the pre-donation screening visit before the first donation and of each fifth whole blood
153 donation. If ferritin levels are >30 ng/mL, donors are eligible to donate at regular donation intervals.
154 If ferritin levels are \leq 30 ng/mL but \geq 15 ng/mL, repeat donors are deferred for six months; new
155 donors are allowed to donate, but ferritin is measured again at this first donation, after which they
156 follow the repeat donor policy. If ferritin levels are <15 ng/mL, new and repeat donors are deferred
157 from donating for twelve months. Ferritin levels are measured again in the donation after this
158 extended interval. Donor physicians may additionally advise donors to visit their general practitioner
159 and/or donate at a lower frequency.¹⁷

160

161 *Outcome assessment*

162 Before the trial, we established four measurement points: 1) one week before implementation
163 (baseline), 2) midway through implementation, 3) one week after full implementation, and 4) one
164 year after full implementation of ferritin-guided donation intervals. Primary outcomes included Hb
165 and ferritin levels, Hb deferral, iron deficiency, and donor return rates, while secondary outcomes
166 encompassed iron deficiency-related symptoms and the impact on the blood supply. Pseudonymized
167 data on age, sex, Hb levels, and deferrals were extracted from the blood bank database (eProgesa
168 software application; MAK-SYSTEM, Paris, France) for donors who visited a blood collection center
169 during a measurement week and consented to their information and leftover materials being used
170 for research. Donor return was defined as attempting a donation within six months after becoming
171 eligible to donate again, accounting for minimum donation intervals and possible deferrals. We
172 measured ferritin levels on the Architect i2000sr (Abbott Diagnostics) in plasma samples collected at
173 donation in K3EDTA tubes (VACUETTE®, Greiner Bio-One, Kremsmünster, Austria) and stored at -30°C
174 for three to 24 months.¹⁹

175

176 New and repeat donors in fixed blood collection centers during measurement week 2 and 3 that
177 provided informed consent were asked to complete questionnaires. These questionnaires assess
178 physical and mental wellbeing (SF-36), fatigue (Checklist Individual Strength), donation-related
179 symptoms, restless legs syndrome (RLS) and pica, cognitive functioning (Cognitive Failure
180 Questionnaire), and warm glow.^{12,17,20-23} Questionnaires were completed using Qualtrics XM®
181 software (Provo, UT, USA) during or shortly after the donation.¹⁷

182

183 We aimed to assess the impact of the new policy on the blood supply by comparing operational data
184 from the blood bank during and one year before and after the study period. We gathered data on
185 whole blood donations, donors and donations invitations from the blood bank database (eProgesa
186 software application; MAK-SYSTEM, Paris, France). Available donors were defined as not being

187 deferred for medical (iron-related or other), travel or lifestyle factors; new donors as showing up for
188 the pre-donation screening; and lapsed donors when they deregistered or did not respond to 5
189 subsequent invitations. Demands for each year were based on hospital requests and converted to
190 blood units.

191

192 *Data analyses*

193 Descriptive statistics are provided for the donors measured during measurement week 1. Using
194 donors measured during all four weeks, we conducted complete case analysis and used ordinary
195 least squares regression in case of continuous outcomes and logistic regression for binary outcomes.
196 After diagnostic tests of linearity and errors assumptions, a log base 10 transformation was applied to
197 improve linearity of ferritin. We conducted robust regression to analyze cognitive functioning,
198 physical health, mental health and fatigue, as the normality assumption for logistic regression was
199 violated. Measurements after implementation were grouped in periods of 6 months and compared
200 to the control condition. The control condition was defined as no implementation of the new policy
201 or implementation less than 6 months ago. Analyses were adjusted for age, weight and height, and
202 stratified by sex and menopausal status. Donor return analyses were adjusted for return being during
203 a COVID-19 lockdown. Null hypotheses are that there are no associations between implementation
204 of the new policy and the outcomes. A two-sided p-value of <0.05 is considered statistically
205 significant and a Bonferroni correction is applied. Statistical analyses were conducted using the R
206 language and environment for statistical computing (4.1.1) and the lme4 (1.1.33), car (3.1.2), lmtest
207 (0.9.40), sandwich (3.0.2), olsrr (0.5.3), and robustbase (0.95.1) packages.^{24–30} HTML files of the
208 scripts and results produced in Quarto are available on GitHub through
209 <https://github.com/Sanquin/FINDEM>.³¹

210

211 *Deviations from protocol*

212 As the number of donors with low ferritin was higher than anticipated after implementation in the
213 first group, further implementation was executed in smaller steps to mitigate the impact on the
214 blood supply.¹⁷ Additional ferritin measurements were done on samples from all donations one year
215 after the third measurement round (between November 23rd and 27th 2020). This fourth time point
216 enables evaluation of long-term results. We furthermore deviated from the protocol by using
217 ordinary least squares regression instead of linear mixed models. In the linear mixed models for
218 analysis of the primary outcomes with random effects for the donation center clusters, the ICC
219 ranged from 0.00 to 0.05; R^2 did not improve with random effects; and residual variance exceeded
220 the variance between clusters. This indicates that the random effects of the donation center clusters
221 were of minimal importance and justifies the use of linear regression models. We conducted
222 sensitivity analyses for donor return, stratifying by ferritin level, reason for deferral, and donation
223 center type. Lastly, we added a sixth element (impact on the blood supply) to the research question
224 and accordingly adjusted the methods.

225

226 **Results**

227 A total of 412,888 whole blood donors made 1,634,700 donations during the study period. We
228 performed measurements in samples of 37,621 donations by 36,099 donors (Figure 1). Table 1 shows
229 the characteristics of donors by sex and randomization group in measurement week 1, in Table S1
230 they are compared to measurements from week 4. Overall, across the randomization groups, donor
231 characteristics were well balanced and comparable with the general donor population (Table 1).³²
232 Characteristics of the 7,573 participants in the questionnaire in measurement week 2 are provided in
233 Table S2.

234

235 Figure 2 shows that the prevalence of iron deficiency and Hb deferral decreased after
236 implementation of the policy. Ferritin-guided donation intervals are associated with significantly
237 higher ferritin and Hb levels and less iron deficiency and Hb deferrals (Figure 3a). Compared to pre-

238 implementation, the intervention was associated with up to 0.24 ng/mL higher log₁₀ ferritin and 0.37
239 g/dL higher Hb at 36 months after implementation in males (Figure 3a). In premenopausal and
240 postmenopausal females, we also observe positive, but smaller, associations with an increasing trend
241 over time. Moreover, the odds ratio of 0.19 indicates that males are 81% less likely to be iron
242 deficient at 36 months after implementation than before the intervention (Figure 3a). In
243 postmenopausal females, odds ratios also decrease over the course of the trial, with iron deficiency
244 being 87% less likely at 36 months after implementation compared to pre-implementation (Figure
245 3a). Hb deferral in males was up to 77% less likely as time since implementation increased, compared
246 to pre-implementation. Similarly, in premenopausal females, Hb deferral is up to 44% less likely at
247 30-35 months after implementation than at pre-implementation (Figure 3a). In postmenopausal
248 females, Hb deferral is up to 51% less likely at 36 months after implementation than at pre-
249 implementation.

250

251 After adjustment for return being during a COVID-19 lockdown, odds for donor return within six
252 months are lower at each time point after implementation compared to pre-implementation (Figure
253 3a). Generally, the negative association with donor return was stronger in males. At 36 months after
254 implementation, males were 42% less likely to return for donation (Figure 3a). For premenopausal
255 and postmenopausal females, we do not observe a consistent decrease in odds over time (Figure 3a).
256 Tables S4-6 show that the differences in odds between groups of ferritin levels, reasons for deferral
257 and donation center types are mostly not statistically significant.

258

259 There were no consistent significant patterns for pica, fatigue, cognitive functioning, the SF-36, and
260 warm glow after implementation of the new policy (Figure 3b). However, males and premenopausal
261 and postmenopausal females were 49%, 127%, and 127% more likely to report RLS at 24 months
262 after implementation than before implementation.

263

264 Table 2 shows that during the implementation of the policy, the donation target and number of
265 donations decreased, but the number of invitations needed to obtain one donation increased. The
266 average donation frequency of donors decreased over the years and subsequently the number of
267 donors that donated increased. The number of available donors increased and the proportion that
268 donated fluctuated between 80 and 90% over the years. The number of simultaneously unavailable
269 donors stabilized at around 40,000 donors per year. While the percentage of low ferritin deferrals
270 increased as a result of the implemented policy, the percentage of low-Hb deferrals decreased. The
271 number of new donors at the blood bank was higher in 2019 and 2020 than in other years, while the
272 number of lapsed donors in 2019 was exceptionally low.

273

274 **Discussion**

275 This stepped-wedge cluster-randomized trial in whole blood donors shows that ferritin and Hb levels
276 are significantly higher and iron deficiency and Hb deferral significantly lower after the
277 implementation of ferritin-guided donation intervals compared to the prior standard of Hb
278 monitoring only. Conversely, we found that the odds of donor return within six months decreased
279 substantially with this policy. Most iron deficiency-related symptoms remained unaffected, except for
280 an increase in reports of RLS. The continuity of the blood supply was maintained, but additional
281 efforts were required to account for the decreased donor availability.

282

283 Ferritin-guided donation intervals were associated with significantly less iron deficiency and higher
284 ferritin and Hb levels compared to pre-implementation, consistent with findings from donor
285 population simulations assessing ferritin testing's impact.³³ The weaker effects observed in
286 premenopausal females could be due to their already less frequent donations before the policy,
287 driven by longer donation intervals and more frequent low-Hb deferrals, providing more recovery
288 time.^{34,35} Additionally, because of more stable iron stores due to the healthy donor effect, combined

289 with lower donation frequency and ferritin levels in this group, may result in less pronounced
290 improvements compared to other groups.^{36,37}

291

292 Our finding that the new policy is associated with significantly lower odds of donor return supports
293 previous findings on decreased return rates after deferral, but may additionally be explained by the
294 negative effects of the COVID-19 pandemic on blood donation intentions, as donors measured after
295 full implementation were slated to return during COVID-19 lockdowns.^{35,38-40} The weaker negative
296 association with donor return in premenopausal compared to other groups may again be explained
297 by their exposure to more frequent deferral through the old Hb monitoring policy.

298

299 The increased reporting of RLS seems surprising, but may simply be a result of increased awareness
300 through information provided to donors upon implementation in their donation center. Further
301 investigation shows no statistically significant correlation between RLS and ferritin levels. The lack of
302 improvement we found in self-reported iron deficiency-related symptoms may partially be due to the
303 small number of questionnaire participants before implementation. However, our findings align with
304 previous randomized placebo-controlled trials investigating iron repletion and self-reported donor
305 health.⁴¹⁻⁴³ Moreover, the benevolence and warm glow that drive donors may overshadow negative
306 health consequences.²³ More functional and objective measures of iron deficiency-related symptoms
307 like fatigue are thus needed. Positive effects of the steady reduction in iron deficiency and Hb
308 deferral on self-reported iron deficiency-related symptoms may be delayed and require longer
309 follow-up in future studies.

310

311 Given the results of this trial regarding donor health and the continued fulfillment of the donation
312 target during and after the implementation of ferritin-guided donation intervals, Sanquin decided to
313 keep the policy in place. Our findings do, however, raise some important policy and practical
314 considerations. First, it provides policymakers with a monitoring option that requires no effort from

315 blood donors, may be more effective in protecting iron status than standard Hb monitoring practices,
316 and does not impose a risk of side effects compared to iron supplementation.¹⁰ However, the
317 decreasing donor availability due to decreasing odds of donor return and increased numbers of
318 deferred donors stress the need for intensified donor recruitment and retention efforts.³⁴ This is
319 reflected in the blood bank practice, as more invitations are needed to obtain one donation.
320 Moreover, as donation frequencies decreased after implementation of the policy, more donors were
321 needed to reach donation demands. To increase donor availability, iron supplementation can be
322 considered as an alternative or additional strategy.^{33,44}

323

324 To our knowledge, this is the first randomized study that goes beyond the limitations of Hb
325 monitoring by evaluating the effectiveness of ferritin-guided donation intervals in improving Hb and
326 ferritin levels, donor return rates and decreasing iron deficiency, Hb deferrals, iron deficiency-related
327 symptoms. One of the major strengths is the stepped-wedge cluster randomized approach as it
328 allows simultaneous implementation and evaluation of a new policy. However, there are also
329 limitations to this study. The nature of the intervention poses a risk of overestimating the positive
330 effect of ferritin-guided donation intervals. Donors whose donation intervals are extended, may not
331 return frequently, potentially resulting in selection bias. The risk of overestimation is to some extent
332 minimized as the duration of the trial exceeds the length of extended donation intervals. There may
333 even be underestimation of the effect on iron deficiency, as cut-offs for iron deficiency used in this
334 study are lower than suggested in literature.^{45,46} There may also be undetected delayed effects in this
335 trial, because ferritin levels are measured at every fifth donation, and thus individual donors may not
336 be confronted with the policy immediately upon implementation in their donation center.

337

338 The FIND'EM study provides substantial evidence that ferritin-guided donation intervals increase Hb
339 and ferritin levels and thereby effectively prevent iron deficiency and Hb deferral, while efforts are
340 needed to mitigate effects on the blood supply. Future studies may investigate long-term effects on

341 donor health outcomes. Our results may help blood services worldwide to improve their donor iron
342 management policies in order to protect donors from developing iron deficiency.

343

344 **Declarations**

345 *Ethics approval and consent to participate*

346 Sanquin's Ethical Advisory Board has reviewed and approved the FIND'EM protocol. Only data from
347 donors who gave consent for their information and left-over material to be used for research
348 purposes at the health check were included in the study. Donors who completed questionnaires
349 provided informed consent for their questionnaire data to be matched with data from the donor
350 database.

351

352 **Competing interests**

353 The authors declare that they have no competing interests.

354

355 **Funding**

356 The current project is supported by the 'Product and Process Development Cellular Products Grant'
357 (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee, Sanquin,
358 Amsterdam, The Netherlands.

359

360 **Authors' contributions**

361 KvdH designed the study. KvdH, MS, FP and FQ set up and coordinated data collection. AM, and SR
362 wrote the analysis plan and drafted the manuscript. AM, SR and FP conducted the analyses with
363 support from EH. The manuscript was critically reviewed and approved by all co-authors.

364

365 **Acknowledgements**

366 We would like to acknowledge all blood bank staff for their commitment to the implementation of
367 the policy and their efforts in collecting data for our study. We are thankful to all donors for their
368 contribution to the study and the blood supply.

References

1. WHO. Blood safety and availability. <https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability>
2. Prinsze FJ, de Groot R, Timmer TC, Zalpuri S, van den Hurk K. Donation-induced iron depletion is significantly associated with low hemoglobin at subsequent donations. *Transfusion*. 2021;61(12):3344-3352. doi:10.1111/trf.16688
3. Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion. *Transfus Med*. 2008;18(1):13-27. doi:10.1111/j.1365-3148.2007.00818.x
4. Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. *Transfusion*. 2006;46(10):1667-1681. doi:10.1111/j.1537-2995.2006.00969.x
5. Brittenham GM. Iron balance in the red blood cell donor. *Dev Biol (Basel)*. 2005;120:77-82.
6. Vinkenoog M, van den Hurk K, van Kraaij M, van Leeuwen M, Janssen MP. First results of a ferritin-based blood donor deferral policy in the Netherlands. *Transfusion*. 60(8):1785-1792. doi:10.1111/trf.15906
7. Boulton F. Managing donors and iron deficiency. *Vox Sang*. 2004;87 Suppl 2:22-24. doi:10.1111/j.1741-6892.2004.00448.x
8. Schotten N, Pasker-de Jong PC, Moretti D, et al. The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism. *Blood*. 2016;128(17):2185-2188. doi:10.1182/blood-2016-04-709451
9. Alvarez-Ossorio, Kirchner, Klüter, Schlenke. Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. *Transfusion Medicine*. 2000;10(2):107-112. doi:<https://doi.org/10.1046/j.1365-3148.2000.00239.x>
10. Smith GA, Fisher SA, Doree C, Di Angelantonio E, Roberts DJ. Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. *Cochrane Database Syst Rev*. 2014;(7):CD009532. doi:10.1002/14651858.CD009532.pub2
11. Baart AM, van den Hurk K, de Kort WL. Minimum donation intervals should be reconsidered to decrease low hemoglobin deferral in whole blood donors: an observational study. *Transfusion*. 2015;55(11):2641-2644. doi:10.1111/trf.13195
12. Di Angelantonio E, Thompson SG, Kaptoge S, et al. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. *Lancet*. 2017;390(10110):2360-2371. doi:10.1016/S0140-6736(17)31928-1
13. Spencer B. Blood donor iron status: are we bleeding them dry? *Curr Opin Hematol*. 2013;20(6):533-539. doi:10.1097/MOH.0b013e32836589f2
14. Simon TL, Garry PJ, Hooper EM. Iron stores in blood donors. *Jama*. 1981;245(20):2038-2043.
15. Cable RG, Brambilla D, Glynn SA, et al. Effect of iron supplementation on iron stores and total body iron after whole blood donation. *Transfusion*. 2016;56(8):2005-2012. doi:10.1111/trf.13659

16. WHO. Guidelines on Assessing Donor Suitability for Blood Donation. In: *Blood Donor Selection*. ; 2012. <https://www.ncbi.nlm.nih.gov/pubmed/23700651>
17. Sweegers MG, Zalpuri S, Quee FA, et al. Ferritin measurement IN Donors—Effectiveness of iron Monitoring to diminish iron deficiency and low haemoglobin in whole blood donors (FIND’EM): study protocol for a stepped wedge cluster randomised trial. *Trials*. 2020;21(1):823. doi:10.1186/s13063-020-04648-w
18. European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). *Guide to the Preparation, Use and Quality Assurance of Blood Components*. European Directorate for the Quality of Medicines and HealthCare; 2017.
19. Moazzen S, Sweegers MG, Janssen M, Hogema BM, Hoekstra T, Van Den Hurk K. Ferritin Trajectories over Repeated Whole Blood Donations: Results from the FIND+ Study. *JCM*. 2022;11(13):3581. doi:10.3390/jcm11133581
20. Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30(6):473-483.
21. Vercoulen JHMM; SCMA; FJFM; GJMD; van der MJWM; BG. de Checklist Individual Strength (CIS). *Gedragstherapie*. 1999;32:131-136.
22. Van den Hurk K, Peffer K, Habets K, et al. Blood donors’ physical characteristics are associated with pre- and post-donation symptoms - Donor InSight. *Blood Transfus*. 2017;15(5):405-412. doi:10.2450/2016.0023-16
23. Ferguson E, Atsma F, de Kort W, Veldhuizen I. Exploring the pattern of blood donor beliefs in first-time, novice, and experienced donors: differentiating reluctant altruism, pure altruism, impure altruism, and warm glow. *Transfusion*. 2012;52(2):343-355. doi:10.1111/j.1537-2995.2011.03279.x
24. R Core Team. R: a language and environment for statistical computing. Published online 2020.
25. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using **lme4**. *J Stat Soft*. 2015;67(1). doi:10.18637/jss.v067.i01
26. Fox J, Weisberg S. *An R Companion to Applied Regression*. Third edition. SAGE; 2019.
27. Zeileis A, Hothorn T. Diagnostic Checking in Regression Relationships. *R News*. 2002;2(3):7-10.
28. Zeileis A. Object-Oriented Computation of Sandwich Estimators. *Journal of Statistical Software*. 2006;16(9):1-16. doi:10.18637/jss.v016.i09
29. Hebbali A. *Olsrr: Tools for Building OLS Regression Models*.; 2020. <https://CRAN.R-project.org/package=olsrr>
30. Todorov V, Filzmoser P. An Object-Oriented Framework for Robust Multivariate Analysis. *Journal of Statistical Software*. 2009;32(3):1-47.
31. Allaire JJ, Teague C, Scheidegger C, Xie Y, Dervieux C. Quarto. Published online January 2022. doi:10.5281/zenodo.5960048

32. Timmer TC, de Groot R, Habets K, et al. Donor InSight: characteristics and representativeness of a Dutch cohort study on blood and plasma donors. *Vox Sang*. 2019;114(2):117-128. doi:10.1111/vox.12731
33. Richard P, Fillet A, Malard L, et al. Impact of donor ferritin testing on iron deficiency prevention and blood availability in France: A cohort simulation study. *Vox Sanguinis*. 2023;118(1):24-32. doi:10.1111/vox.13377
34. Spekman MLC, Ramondt S, Sweegers MG. Whole blood donor behavior and availability after deferral: Consequences of a new ferritin monitoring policy. *Transfusion*. 2021;61(4):1112-1121. doi:10.1111/trf.16235
35. Spekman MLC, Tilburg TG, Merz E. Do deferred donors continue their donations? A large-scale register study on whole blood donor return in the Netherlands. *Transfusion*. 2019;59(12):3657-3665. doi:10.1111/trf.15551
36. Moazzen S, sweegers M, Hogema B, Hoekstra T, van den Hurk K. Ferritin trajectories over repeated whole blood donations: results from the FIND+ study. *medRxiv*. Published online 2021:2021.12.13.21267744. doi:10.1101/2021.12.13.21267744
37. Atsma F, Veldhuizen I, Verbeek A, de Kort W, de Vegt F. Healthy donor effect: its magnitude in health research among blood donors. *Transfusion*. 2011;51(8):1820-1828. doi:10.1111/j.1537-2995.2010.03055.x
38. Custer B, Chinn A, Hirschler NV, Busch MP, Murphy EL. The consequences of temporary deferral on future whole blood donation. *Transfusion*. 2007;47(8):1514-1523. doi:10.1111/j.1537-2995.2007.01292.x
39. Custer B, Schlumpf KS, Wright D, et al. Donor return after temporary deferral. *Transfusion*. 2011;51(6):1188-1196. doi:10.1111/j.1537-2995.2010.02989.x
40. Veseli B, Sandner S, Studte S, Clement M. The impact of COVID-19 on blood donations. Dickert S, ed. *PLoS ONE*. 2022;17(3):e0265171. doi:10.1371/journal.pone.0265171
41. Hod EA, Brittenham GM, Bitan ZC, et al. A randomized trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and well-being. *Blood*. 2022;140(25):2730-2739. doi:10.1182/blood.2022017288
42. Waldvogel S, Pedrazzini B, Vaucher P, et al. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. *BMC Med*. 2012;10:8. doi:10.1186/1741-7015-10-8
43. Keller P, von Känel R, Hincapié CA, et al. The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial. *Sci Rep*. 2020;10(1):14219. doi:10.1038/s41598-020-71048-0
44. Karregat J, Sweegers MG, Quee FA, et al. Ferritin-guided iron supplementation in whole blood donors: optimal dosage, donor response, return and efficacy (FORTE)-a randomised controlled trial protocol. *BMJ Open*. 2022;12(3):e056316-e056316. doi:10.1136/bmjopen-2021-056316
45. Galetti V, Stoffel NU, Sieber C, Zeder C, Moretti D, Zimmermann MB. Threshold ferritin and hepcidin concentrations indicating early iron deficiency in young women based on upregulation of iron absorption. *EClinicalMedicine*. 2021;39:101052. doi:10.1016/j.eclinm.2021.101052

46. Tarancon-Diez L, Genebat M, Roman-Enry M, et al. Threshold Ferritin Concentrations Reflecting Early Iron Deficiency Based on Hepcidin and Soluble Transferrin Receptor Serum Levels in Patients with Absolute Iron Deficiency. *Nutrients*. 2022;14(22):4739. doi:10.3390/nu14224739




Figure 1. Stepped-wedge cluster randomized trial design and timing of intervention rollout (n displayed represents donations).






Figure 2. Percentage of low Hb and ferritin deferral per sex in controls and at six timepoints post-intervention.

A Associations of implementation of ferritin-guided donation intervals with primary study outcomes



Ferritin: log₁₀ ng/mL; Hb: g/dL; Iron deficiency: ferritin < 15 ng/mL; Hb deferral: males < 13.5 g/dL, females < 12.5 g/dL; Return: within 6 months of first allowed date. Reference group: no implementation and 0-5 months since implementation. All analyses are adjusted for age, height and weight. Return is additionally adjusted for whether return would be during first COVID lockdown (March-May 2020). Statistical significance: Bonferroni correction applied to adjust for multiple testing (0.05/6).

B Associations of implementation of ferritin-guided donation intervals with secondary study outcomes



Statistical significance: Bonferroni correction applied to adjust for multiple testing (0.05/6). Cognitive functioning: higher score indicates worse result. Physical & mental health: higher score indicates better result.

Figure 3. Results of regression analyses for iron-related outcomes, donor return and iron-deficiency related symptoms. Corresponding coefficients, confidence intervals and p-values are displayed in Table S3.

Table 1. Donor characteristics in measurement week 1, where group 1 had just implemented the new policy and groups 2, 3, and 4 were considered controls.

	Group 1 ¹	Group 2	Group 3	Group 4	Overall
Pre-menopausal, female donors	N = 688	N = 590	N = 634	N = 465	N = 2,377
New donors, N (%)	167 (24.3)	109 (18.5)	131 (20.7)	86 (18.5)	493 (20.7)
Age (years), median [IQR]	25.0 [21.0, 33.0]	26.0 [21.0-34.0]	26.0 [22.0-33.8]	25.0 [21.0-31.0]	25.0 [21.0-33.0]
Height (cm), mean (SD)	171 (6.4)*	171 (6.9)	171 (6.3)*	171 (6.4)	171 (6.5)*
Weight (kg), mean (SD)	71.0 (12.2)*	71.0 (12.4)	71.4 (11.9)	70.8 (12.1)	71.1 (12.2)*
Hemoglobin, median [IQR], g/dL	13.4 [12.7-12.4]	13.4 [12.9-14.0]	13.5 [12.9-14.0]	13.4 [12.9-14.0]	13.4 [12.9-14.0]
Low hemoglobin deferral (<12.5 g/dL), N (%)	64 (9.3)	34 (5.8)	46 (7.3)	43 (9.2)	187 (7.9)
Ferritin, median [IQR], ng/mL	26.2 [13.3-46.2]**	24.4 [12.1-46.7]**	24.7 [12.7-45.5]**	23.7 [10.3-40.3]**	25.1 [12.3-45.4]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	161 (23.4)**	159 (26.9)**	173 (27.3)**	130 (28.0)**	623 (26.2)**
Total number of whole blood donations, median [IQR]	2.0 [1.0-7.0]	3.0 [1.0-9.0]	4.0 [1.0-10.0]	3.0 [1.0-9.0]	3.0 [1.0-9.0]
Number of whole blood donations in the past 2 years, median [IQR]	2.0 [1.0-4.0]	2.0 [1.0-4.0]	2.0 [1.0-4.0]	3.0 [1.0-4.0]	2.0 [1.0-4.0]
Donor return within 6 months of first allowed date, N (%)	478 (66.5)	383 (64.9)	436 (68.8)	323 (69.5)	1,620 (68.2)
Post-menopausal, female donors	N = 388	N = 379	N = 387	N = 308	N = 1,462
New donors, N (%)	11 (2.8)	7 (1.8)	13 (3.4)	2 (0.6)	33 (2.3)
Age (years), median [IQR]	55.0 [49.0-60.0]	55.0 [50.0-61.0]	56.0 [49.0-60.0]	55.0 [49.8-62.0]	55.0 [50.0-61.0]
Height (cm), mean (SD)	170 (5.9)	169 (6.1)	170 (6.2)	170 (5.9)	170 (6.0)
Weight (kg), mean (SD)	74.5 (11.3)	73.4 (12.3)	73.9 (12.4)	73.3 (11.6)	73.8 (11.9)
Hemoglobin, median [IQR], g/dL	13.9 [13.1-14.5]	13.5 [13.1-14.5]	13.7 [13.1-14.3]	13.5 [13.1-14.3]	13.7 [13.1-14.3]
Low hemoglobin deferral (<12.5 g/dL), N (%)	19 (4.9)	19 (5.0)	21 (5.4)	11 (3.6)	70 (4.8)
Ferritin, median [IQR], ng/mL	27.4 [13.5-44.0]***	28.3 [14.0-45.8]**	25.7 [13.2-45.0]**	26.7 [15.0-43.6]**	27.4 [13.7-45.0]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	85 (21.9)***	87 (23.0)**	95 (24.5)**	64 (20.8)**	331 (22.6)**
Total number of whole blood donations, median [IQR]	29.0 [11.0-50.0]	26.0 [12.0-42.0]	29.0 [12.0-46.0]	29.0 [12.0-47.0]	28.0 [12.0-46.0]
Number of whole blood donations in the past 2 years, median [IQR]	5.0 [3.0-5.0]	4.0 [3.0-5.0]	5.0 [3.0-6.0]	5.0 [3.0-5.0]	5.0 [3.0-6.0]
Donor return within 6 months of first allowed date, N (%)	297 (76.5)	292 (77.0)	310 (80.1)	237 (76.9)	1,136 (77.7)
Male donors	N = 1075	N = 1061	N = 1007	N = 870	N = 4,013
New donors, N (%)	58 (5.4)	63 (5.9)	46 (4.6)	47 (5.4)	214 (5.3)
Age (years), median [IQR]	48.0 [32.0-58.5]	51.0 [35.0-60.0]	49.0 [32.5-58.0]	49.0 [31.0-59.0]	49.0 [32.0-59.0]
Height (cm), mean (SD)	184 (7.1)	183 (7.2)	183 (6.9)	183 (7.5)	183 (7.2)
Weight (kg), mean (SD)	86.5 (12.1)	85.8 (12.2)	85.4 (12.0)	85.4 (11.9)*	85.8 (12.1)
Hemoglobin, median [IQR], g/dL	14.8 [14.2-15.6]	14.8 [14.2-15.6]	14.8 [14.2-15.6]	14.8 [14.2-15.5]	14.8 [14.2-15.6]
Low hemoglobin deferral (<13.5 g/dL), N (%)	42 (3.9)	27 (2.5)	34 (3.4)	27 (3.1)	130 (3.2)
Ferritin, median [IQR], ng/mL	25.3 [12.3-54.9]**	25.9 [13.2-55.3]**	24.8 [12.4-50.0]**	24.5 [11.6-54.8]**	25.2 [12.4-53.2]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	280 (26.0)**	273 (25.7)**	272 (27.0)**	243 (27.9)**	1,068 (26.6)**
Total number of whole blood donations, median [IQR]	30.0 [7.0-68.0]	39.0 [8.0-71.0]	32.0 [8.0-64.0]	31.5 [7.0-70.0]	32.0 [7.0-68.0]
Number of whole blood donations in the past 2 years, median [IQR]	6.0 [4.0-9.0]	6.0 [4.0-9.0]	6.0 [4.0-8.0]	6.0 [4.0-8.0]	6.0 [4.0-8.0]

[IQR]					
Donor return within 6 months of first allowed date, N (%)	924 (86.0)	905 (85.3)	870 (86.4)	738 (84.8)	3,437 (85.6)

¹Randomly assigned clusters of donation centres (Group 1-3: 8 clusters, group 4: 5 clusters)

Missing: * < 10%, ** 10-20%, *** > 20%

Table 2. Blood bank statistics to describe impact of new policy on blood supply in the Netherlands. Ferritin-guided donation intervals were implemented in a step-wise manner from November 2017 onwards. Hence, there is no data on prolonged intervals due to low ferritin in 2016. In November 2019 implementation was completed and in November 2020 the study was completed. All statistics

	2016	2017	2018	2019	2020	2021	2022
Hospital demand (in donation units)	418,491	407,215	406,199	407,460	402,578	400,757	392,805
Donations	421,019	410,956	412,266	412,479	411,021	406,845	393,633
Donors	234,821	234,224	237,985	248,911	278,863	262,956	260,033
Average donation frequency	1.79	1.75	1.73	1.66	1.47	1.55	1.51
Average invitations per donation	2.83	2.95	3.03	3.12	3.19	3.41	3.59
Low ferritin							
Number of donations	-	1,979	19,044	45,829	60,938	63,695	66,635
Percentage of donations	-	0.48	4.62	11.11	14.83	15.66	16.93
Unique donors	-	1,973	17,441	38,961	53,841	51,140	45,696
Hb deferral							
Number of donations	38,143	39,083	37,733	30,411	20,479	21,589	21,494
Percentage of donations	9.06	9.51	9.15	7.37	4.98	5.31	5.46
Unique donors	32,008	32,844	31,539	26,222	20,599	16,813	17,820
Available donors (Dec 31)	286,597	273,379	283,550	305,225	312,930	308,751	322,637
Unavailable donors due to low ferritin	-	1,973	14,435	32,585	42,709	39,570	38,901
Available donors invited to donate (%)	81.93	85.68	83.93	81.55	80.11	85.17	80.60
New donors	50,107	44,362	58,419	60,121	71,983	54,194	53,194
Lapsed donors	49,066	51,579	42,782	26,571	47,918	55,341	29,982

are presented only for whole blood donations.